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Activated Ras but not Raf can transform RIE-1 and
other epithelial cells, indicating the critical importance
of Raf-independent effector function in Ras transforma-
tion of epithelial cells. To elucidate the nature of these
Raf-independent activities, we utilized representational
difference analysis to identify genes aberrantly ex-
pressed by Ras through Raf-independent mechanisms in
RIE-1 cells. We identified a total of 22 genes, both known
and novel, whose expression was either activated (10) or
abolished (12) by Ras but not Raf. The genes up-regu-
lated encode proteins involved in protein or DNA syn-
thesis, regulation of protease activity, or ligand binding,
whereas those genes down-regulated encode actin cy-
toskeletal-, extracellular matrix-, and gap junction-asso-
ciated proteins, and transmembrane receptor- or cyto-
kine-like proteins. These results suggest that a key
function of Raf-independent signaling involves deregu-
lation of gene expression. We further characterized
transgelin as a gene whose expression was abolished by
Ras. Transgelin was identified previously as a protein
whose expression was lost in virally transformed cell
lines. We show that this loss is regulated at the level of
gene expression and that both Raf-dependent and Raf-
independent pathways are required to cause Ras down-
regulation of transgelin in RIE-1 cells, whereas Raf
alone is sufficient to cause its loss in NIH 3T3 fibro-
blasts. We also found that Ras-dependent and Ras-inde-
pendent mechanisms can cause the down-regulation of
transgelin in human breast and colon carcinoma cells
lines and patient-derived tumor samples. We conclude
that loss of transgelin gene expression may be an impor-
tant early event in tumor progression and a diagnostic
marker for breast and colon cancer development.
Mutations in ras genes are found in 30% of all human
cancers (1, 2). Therefore, a significant research effort has been
made to elucidate the function of Ras in normal and neoplastic
cells. In particular, much is now known regarding the function
of Ras in signal transduction (3, 4). Ras is activated by a diverse
spectrum of extracellular stimuli. Once activated, Ras interacts
with downstream effectors and stimulates cytoplasmic signal-
ing cascades that regulate events in the cytoplasm and nucleus.
Cytoplasmic events include reorganization of the actin cy-
toskeleton and modulation of cell shape and cell movement (5).
Nuclear events include regulation of cell cycle progression and
gene transcription (6, 7). Mutated Ras proteins found in tumors
are constitutively activated in the absence of extracellular
stimuli, cause persistent signaling, promoting morphologic and
growth transformation.
Ras interacts with a spectrum of functionally diverse effec-
tors to mediate its diverse functions (3, 4). The best character-
ized are the Raf serine/threonine kinases (8). Ras binds and
promotes the activation of Raf, which in turn activates the
MEK1/2 dual specificity kinases, which activate the ERK1 mi-
togen-activated protein kinases (MAPKs). Activated ERKs
then translocate to the nucleus where they phosphorylate and
activate Ets family transcription factors. Ras also activates two
other MAPK cascades, the JNK and p38 MAPKs, via Raf-
independent effectors that activate the Rac small GTPase (9).
JNK and p38 activation can also regulate the activity of tran-
scription factors, such as c-Jun and ATF-2, respectively.
Phosphatidylinositol 3-kinases are a second family of effec-
tors involved in Ras transformation (10). Phosphatidylinositol
3-kinase activation of Akt can activate the NF-B transcription
factor and promote cell survival (11, 12). Members of the Ral-
GDS family of guanine nucleotide exchange factors are activa-
tors of Ral small GTPases and represent the third best char-
acterized family of Ras effectors (13). RalGDS activation can
also regulate transcription factor activity, including NF-B and
Fos (14, 15).
Because Ras signaling can regulate the activities of a variety
of transcription factors, it is likely that Ras transformation is
mediated, in part, by changes in gene expression (7). Consist-
ent with this possibility is the observation that genes with
known functions in oncogenesis contain Ras-responsive pro-
moter elements in their promoters (e.g. Ets, AP-1, and NF-B).
For example, the cyclin D1 promoter contains Ets-, AP-1-, and
NF-B-binding sites, and cyclin D1 transcription and protein
expression are up-regulated persistently in Ras-transformed
cells (6) and required for Ras oncogenesis (16). Additionally,
inhibition of the function of various transcription factors can
block Ras transformation of rodent fibroblasts. For example,
depletion of c-myc with specific antisense sequences (17) or
* This work was supported by National Institutes of Health Grant
CA63071 (to C. J. D.) and Department of Defense Grant DAMD17-00-
1-0552 (to J. M. S.). The costs of publication of this article were defrayed
in part by the payment of page charges. This article must therefore be
hereby marked “advertisement” in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
‡ To whom correspondence should be addressed: Lineberger Compre-
hensive Cancer Center, CB 7295, University of North Carolina, Chapel
Hill, NC 27599-7295. Tel.: 919-962-1057; Fax: 919-966-0162; E-mail:
shieldsj@med.unc.edu.
1 The abbreviations used are: ERK, extracellular signal regulated
kinase; RDA, representational difference analysis; MAPK, mitogen-
activated protein kinase; MEK, MAPK/ERK kinase; DMEM, Dulbecco’s
minimum essential medium; IPTG, isopropyl-thiogalactosidase; FCS,
fetal calf serum; HA, hemagglutinin; GAPDH, glyceraldehyde-3-phos-
phate dehydrogenase; DP, difference products; IMPDH II, IMP dehy-
drogenase II; TLSF-, thymic lymphoma cell stimulating factor-; SDF,
stromal cell-derived factor; BMP, bone morphogenetic protein.
THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 277, No. 12, Issue of March 22, pp. 9790–9799, 2002
© 2002 by The American Society for Biochemistry and Molecular Biology, Inc. Printed in U.S.A.
This paper is available on line at http://www.jbc.org9790
This is an Open Access article under the CC BY license.
expression of dominant negative mutants of Ets-1, Ets-2 (18,
19), c-Fos (20), or c-Jun (21) can block oncogenic Ras-mediated
transformation of NIH 3T3 fibroblasts. c-jun null mouse em-
bryo fibroblasts were found to be insensitive to Ras-mediated
transformation (22). Thus, the deregulated function of these
transcription factors is clearly important for Ras transforma-
tion. However, what remains poorly understood is what genes
are the key targets of Ras important for transformation.
The majority of human cancers in which ras mutations are
found are of epithelial or hematopoietic cell origin (1, 2). De-
spite this, much of our understanding of Ras function is based
on studies of Ras transformation of rodent fibroblast cell lines
(23). Observations that Ras function exhibits significant cell
type differences questions whether the delineation of the Ras
signaling events important for transformation in rodent fibro-
blasts accurately reflect how oncogenic Ras promotes human
oncogenesis. For example, we and others (24, 25)2 showed
previously that although activated Ras and Raf can fully trans-
form NIH 3T3 fibroblast cells, only activated Ras caused trans-
formation of RIE-1, IEC-6, or MCF-10A and HEK human epi-
thelial cells. Although activation of the Raf/MEK/ERK pathway
is necessary for Ras transformation of RIE-1 cells, by itself, Raf
is incapable of causing transformation of these rodent intesti-
nal epithelial cells. Stanbridge and colleagues (26) found that
activation of the Raf/MEK/ERK pathway was necessary for
Ras-induced transformation of a human fibrosarcoma but not a
human colon adenocarcinoma cell line. Gire et al. (27) deter-
mined that although activated Ras was capable of stimulating
a proliferative response in human primary thyroid epithelial
cells, activation of the Raf/MEK/ERK pathway alone was not
able to mimic this proliferative response. Finally, Marshall and
colleagues (28) found that up-regulation of the ERK MAPK
cascade did not correlate with the presence of mutated ras in
pancreatic carcinoma cell lines. Taken together, these studies
demonstrate the importance of Raf-independent pathways in
the transformation of epithelial cells.
To delineate the Raf-independent mechanisms important for
Ras transformation of epithelial cells, we utilized the PCR-
based cDNA subtraction library screening method of represen-
tational difference analysis (RDA) (29, 30), and we identified
genes whose expression was deregulated by activated Ras, but
not Raf, in RIE-1 cells. Our analyses identified both known and
novel genes that were either up- or down-regulated by Ras, but
not Raf, in an essentially all-or-none fashion. These observa-
tions support the important role of Raf-independent effectors in
causing changes in gene expression and the importance of gain
as well as loss of gene expression in Ras-mediated transforma-
tion. Finally, we further characterized the regulation of trans-
gelin, which was identified previously as a protein whose ex-
pression was lost in suspended or virally transformed rodent
cell lines (31). We determined that both Raf-dependent and
Raf-independent signalings are required for Ras to cause down-
regulation of transgelin gene expression in RIE-1 cells,
whereas Raf activation alone was sufficient to cause down-
regulation in NIH 3T3 fibroblasts. Finally, we determined that
Ras-dependent and Ras-independent mechanism can down-
regulate transgelin in breast and colon carcinoma cell lines and
patient-derived tumors, supporting an important contribution
of transgelin loss of function in human oncogenesis.
EXPERIMENTAL PROCEDURES
Cell Lines—RIE-1 rat intestinal epithelial cells are a spontaneously
immortalized, nontransformed, diploid, epidermal growth factor-re-
sponsive cell line (obtained from R. J. Coffey, Jr., Vanderbilt University)
and maintained in Dulbecco’s modified Eagle’s medium (DMEM) sup-
plemented with 5% fetal calf serum (FCS). Mass populations of RIE-1
cell lines stably expressing activated forms of K-Ras4B (K-Ras(12V))
and Raf-1 (Raf-22W) were established by transfection with pZIP-
NeoSV(x)1 retrovirus vectors, where expression of the inserted gene is
regulated by a Moloney long terminal repeat promoter, have been
characterized previously, and are designated RIE(Ras) and RIE(Raf)
cells, respectively (24). Mass populations of RIE-1 cells stably express-
ing constitutively activated forms of RhoA(63L) and Rac1(61L) (32)
were generated in a similar fashion previously.3 The retroviral vector
pCTV3, where expression is controlled by the Moloney long terminal
repeat promoter, was used to generate mass populations of RIE-1 cell
lines stably expressing NH2-terminally deleted, constitutively activated
forms of mouse Vav (pCTV3H-N186-vav) and Dbl (pCTV3H-dblHA1)
(33, 34) similarly to those generated by retroviral infection with pZIP-
NeoSV(x)1 previously.3 Rat transgelin cDNA was PCR-amplified from a
RIE-1 cDNA library, subcloned into a hemagglutinin (HA) epitope-
tagged pBabe-puro retroviral expression vector (designated pBabe-HA-
transgelin), sequenced, and analyzed by comparison to rat transgelin
sequence in GenBankTM (accession number X64422). pBabe-HA-trans-
gelin plasmid DNA was then used to generate virus to infect RIE-1 cells
to establish mass populations of RIE-1 cells stably expressing HA-
transgelin, and protein expression was verified by Western blot analy-
sis with protein lysates resolved over 15% SDS-PAGE gels, transferred
onto Immobilon-P membranes (Millipore), and blotted with anti-HA
serum (Babco).
The MCF-10A human breast epithelial cells, a spontaneously immor-
talized cell line that retains growth properties of normal breast epithe-
lial cells, were obtained from M. Kinch (Purdue University) and main-
tained in DMEM/F-12 supplemented with 5% horse serum, 20 ng/ml
epidermal growth factor, 0.5 g/ml hydrocortisone, and 10 g/ml insu-
lin (35). The MCF-7 human breast ductal carcinoma cell line, provided
by E. Stanbridge (University of California, Irvine), was maintained in
DMEM supplemented with 10% FCS, 1 mM sodium pyruvate, and 8
g/ml insulin. The T47D human breast ductal carcinomas cell line,
provided by P. Keely (University of Wisconsin), was maintained in
RPMI supplemented with 10% FCS, 100 mM sodium pyruvate, and 4
mg/ml insulin. The DLD-1 human colon adenocarcinoma cell line con-
tains one endogenous K-ras(13D) allele, and the derivative cell line of
DLD-1 lacking the mutant K-ras allele (DKO-3) (36), provided by R. J.
Coffey, Jr., was maintained in RPMI supplemented with 10% FCS. The
reduced ability of the DKO-3 variant to form colonies in soft agar and
tumors in athymic nude mice has been described previously (36, 37).
The HT1080 human fibrosarcoma cell line containing one endogenous
mutant N-ras(61K) allele and the derivative cell line of HT1080 lacking
the mutant ras allele (MCH 603c8) were provided by E. Stanbridge and
maintained in DMEM supplemented with 10% FCS, 25 mM HEPES,
and 1 mM sodium pyruvate, and additionally for the 603c8 cells, 1
hypoxanthine/aminopterin/thymidine medium (Sigma) was also added.
The human colon tumor cell lines, provided by L. G. Tillotson (Univer-
sity of North Carolina, Chapel Hill), were as follows: Colo320 HSR and
Colo205 cells were maintained in RPMI 1640 supplemented with 10%
FCS; HT29, HCT116, and CaCo2 cells were maintained in DMEM
supplemented with 10% FCS; and SW480 cells were maintained in
Leibovitz’s medium supplemented with 10% FCS.
Representational Difference Analysis (RDA)—RDA was carried out
essentially as described by Hubank and Schatz (29) and as we have
described previously (30). Total RNA was isolated from RIE(Ras) and
RIE(Raf) cell lines (24) that were cultured and harvested at the same
time to minimize gene expression changes because of cell culture con-
ditions. mRNA Maxi Kit from Qiagen was used to purify mRNA from
total RNA and cDNA prepared with the Superscript Choice Kit (Invitro-
gen) as described by the manufacturers. Tester and driver amplicons
were hybridized to each other at molar ratios of 1:100 (DP1), 1:400
(DP2), 1:80,000 (DP3), and 1:800,000 (DP4) for each successive round of
RDA. After four rounds of hybridization and PCR, the final PCR prod-
ucts were size-fractionated over a 1.4% agarose gel, purified, cloned into
the BamHI site of pBluescript (Stratagene), sequenced, and compared
with the GenBankTM and EST data bases using BLAST algorithms.
Human Tumor Samples—Matched pairs of five colon adenocarcino-
mas and four breast invasive ductal carcinomas tumor samples along
with surrounding marginal nontumor tissue samples were obtained
from the Lineberger Comprehensive Cancer Center’s Tissue Procure-
ment Center at the University of North Carolina, Chapel Hill, and total
RNA was extracted from the tissues as described below.
2 N. M. Hamad, J. Elconin, A. E. Karnoub, W. Bai, J. N. Rich, R. T.
Abraham, C. J. Der, and C. M. Counter, submitted for publication. 3 J. M. Shields, H. Mehta, and C. J. Der, submitted for publication.
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RNA Isolation and Northern Blot Analyses—Total RNA from cul-
tured cells and tumors was isolated by the guanidine thiocyanate,
acid-phenol method (38). For Northern blot analyses, 25 g of total RNA
was size-fractionated over 1.4% formaldehyde gels, transferred to Hy-
bond-N nylon membrane (Amersham Biosciences), and hybridized to
32P-labeled DNA probes. Control for equivalent RNA loading was de-
termined by hybridization with a GAPDH cDNA probe. Hybridizations
were with 2  106 cpm/ml in a solution containing 5 SSC, 50%
formamide, 5 Denhardt’s, 0.5% SDS, 0.1% Nonidet P-40, 50 mM so-
dium phosphate, pH 7.0, and 0.05% sodium pyrophosphate at 42 °C for
24–48 h and washed in 1 SSC with 0.1% SDS at 50 °C followed by
0.2 SSC with 0.1% SDS at 55 °C.
RESULTS
K-Ras (12V) Transformation of Epithelial Cells Causes Ab-
errant Gene Expression—Whereas both activated Ras and Raf
can readily transform NIH 3T3 fibroblasts, only Ras can trans-
form RIE-1 and other epithelial cell lines suggesting that Raf-
independent pathways play a crucial role in transformation of
epithelial cells (24). To assess further the role of Raf-independ-
ent effector function in promoting Ras transformation, we iden-
tified genes aberrantly expressed by oncogenic Ras through
Raf-independent mechanisms in RIE-1 cells using the PCR-
based cDNA subtraction cloning method of RDA (29, 30). Be-
cause our goal was to identify gene expression changes that are
important for the maintenance of oncogenic Ras transforma-
tion, we utilized RIE-1 cells stably expressing constitutively
activated K-Ras4B(12V) or Raf-1 (Raf-22W) (designated RI-
E(Ras) and RIE(Raf), respectively) (24). Thus, the gene expres-
sion changes identified may be caused directly by the activation
of oncogenic Ras function or indirectly as consequence of Ras-
mediated transformation.
To isolate genes up-regulated by Ras, but not Raf, we sub-
tracted cDNA from RIE(Ras) cells with cDNA from RIE(Raf)
cells. By using this approach, genes up-regulated by the Raf/
MEK/ERK pathway were subtracted out leaving only those
genes up-regulated by Ras that required activation of Raf-
independent effector signaling pathways. To isolate genes
down-regulated by Ras, but not Raf, a second subtraction was
performed in the reverse direction. Here we subtracted cDNA
from RIE(Raf) cells with cDNA from RIE(Ras) cells. In this
direction, the absence of cDNA from those genes down-regu-
lated by Ras through Raf-independent pathways allowed for
the cloning of the corresponding cDNAs from the RIE(Raf)
cells.
Fig. 1 shows the difference products (DP) we obtained after
four successive rounds of subtraction and amplification used to
isolate the genes either up-regulated (Ras cDNA subtracted
with Raf cDNA (Ras-Raf), lanes 2–5) or down-regulated (Raf
cDNA subtracted with Ras cDNA (Raf-Ras), lanes 6–9) in RI-
E(Ras) cells. Sequential subtractions resulted in the enrich-
ment of specific bands which represented various genes as we
increased the stringency of each subtraction (compare the
starting cDNA material, lanes 1 (Ras cDNA representation)
and 10 (Raf cDNA representation) to the sequentially sub-
tracted and amplified difference products (DP1 to DP4 for each
subtraction, lanes 2–9)). For our analyses, we concentrated on
the isolation and analyses of sequences from DP4 to identify
those genes whose expression shows a large gain or loss of
expression by Ras, but not Raf, activation.
We first confirmed that the clones isolated from the subtrac-
tions represented truly differentially expressed genes and com-
pared relative expression levels by Northern blot analysis us-
ing total RNA from control, empty vector-transfected RIE-1
cells, RIE(Raf), and RIE(Ras) cells hybridized to 32P-labeled
probes of each clone (Fig. 2). We found that all the isolated
clones did correspond to differentially expressed transcripts
and most were highly differentially expressed in an essentially
all-or-none fashion. Collectively, we identified 10 genes whose
expression was up-regulated and 12 whose expression was
down-regulated, by Ras but not by Raf or vector only express-
ing RIE-1 cells.
After verification of differential expression, the sequences of
the isolated genes were used to search for related sequences in
GenBankTM. As summarized in Tables I and II, our analyses
identified both known and novel genes. Several genes encoding
proteins involved with protein or DNA synthesis were up-
regulated by Ras, but not Raf, including DNA-directed RNA
polymerase II, IMP dehydrogenase type II, and the L27a ribo-
somal protein subunit. In addition to four novel genes found to
be up-regulated by Ras but not Raf (RDA clones 12, 28, 31, and
87), those encoding a putative ligand-binding protein (RY 2G5),
a cartilage matrix proteoglycan (aggrecan), and a serine prote-
ase, nexin I (glial-derived nexin I), were also cloned.
Genes down-regulated by Ras, but not Raf, included three
novel genes (RDA clones 17, 42, and 48), two cytoskeletal
actin-binding proteins (tropomyosin and transgelin), an extra-
cellular matrix protein (collagen -1(I)), a basement membrane
protein (nidogen/entactin), a gap junction protein (connexin-
26), two membrane-bound receptor proteins (protein tyrosine
phosphatase  and ODZ3), and two growth factor type proteins
(bone morphogenetic protein-4 (BMP-4) and thymic lymphoma
cell stimulating factor (TLSF-/SDF-1)).
One of the genes we identified that was strongly down-
regulated by Ras, but not Raf, was transgelin (Fig. 2B). Trans-
gelin (also called SM22 (39)) is an actin-binding protein of
unknown function and has been shown to cross-link actin fila-
ments in vitro (40). Actin stress fibers are commonly reduced in
transformed cells and in cells grown in suspension, and trans-
gelin was shown to bind actin stress fibers in fibroblasts and to
have reduced expression in SV40- and RSV-transformed mes-
enchymal cells and in untransformed 3T3 fibroblasts grown in
suspension (31). Because current understanding of the mecha-
nism by which transgelin protein expression is down-regulated
and the role of this loss in transformation were limited, we
centered our analyses on evaluating these issues.
FIG. 1. Comparison of RDA difference products (DP) gener-
ated from Ras minus Raf (Ras  Raf) and Raf minus Ras (Raf 
Ras) cDNA subtractions. RNA was isolated from exponentially grow-
ing RIE-1 cells stably expressing either activated K-Ras(12V) or Raf-
22W and used in cDNA subtractions and PCR amplifications to isolate
cDNA sequences whose expression is stably deregulated by Ras but not
Raf activation. Each cDNA sample (0.5 g) was resolved by electro-
phoresis over a 1.2% agarose gel from the Ras representation (Ras Reps,
lane 1), DP1–4 from the Ras minus Raf subtraction (lanes 2–5), DP1–4
from the Raf minus Ras subtraction (lanes 6–9), and the Raf represen-
tation (Raf Reps, lane 10). Note the difference in band sizes in the final
difference products (DP4) of the Ras minus Raf (lane 6) when compared
with the Raf minus Ras (lane 7) subtractions.
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Transgelin Down-regulation Represents an Early Event in
Ras-mediated Transformation of RIE-1 Cells—We first wanted
to establish if the down-regulation of transgelin expression is a
direct consequence of Ras activation or, alternatively, is a con-
sequence of Ras-mediated transformation. To determine this,
we utilized a RIE-1 cell line that harbors an isopropylthiogal-
actosidase (IPTG)-inducible expression vector encoding Ha-
Ras(12V) (41). When cultured in the absence of IPTG, no sig-
nificant expression of Ha-Ras(12V) protein was seen, and the
cells exhibited the nonrefractile, cobblestone-like cell morphol-
ogy and anchorage-dependent growth properties characteristic
of untransformed parental RIE-1 cells (data not shown).3 After
exposure to IPTG, expression of Ha-Ras(12V) protein was de-
tected within 6 h (Fig. 3). However, morphologic transforma-
tion was not observed until after 48 h of IPTG treatment, and
complete morphologic transformation was not achieved until
after 72 h (data not shown),3 Thus, this cell line allowed us to
assess whether the loss of expression of transgelin is associated
with Ha-Ras(12V) protein expression or Ha-Ras(12V)-induced
transformation.
We performed Northern blot (transgelin) analyses on cell
lysates from the Ras-inducible RIE-1 cells treated with IPTG
for 0–96 h (Fig. 3). Transgelin mRNA showed a progressive
time-dependent decrease beginning at 6 h and was completely
lost after 24 h. These results suggest that down-regulation of
transgelin expression is caused directly by Ras activation and
is not a consequence of the transformed state induced by Ras.
Thus, the loss of function of transgelin may be an important
event in facilitating Ras transformation.
Ras Down-regulation of Transgelin Shows Cell Type Differ-
ences in the Requirement for Raf-independent Effector Activa-
tion—Because Raf activation alone can cause transformation of
NIH 3T3 mouse fibroblasts, we also determined if Raf-inde-
pendent pathways were also required for Ras-mediated down-
regulation of transgelin in NIH 3T3 cells. Northern blot anal-
yses (Fig. 4A) showed that transgelin was expressed in control
and empty vector-transfected NIH 3T3 cells but lost in NIH
3T3 cells stably expressing either activated Ras or Raf. Thus,
Ras-mediated down-regulation of transgelin does not require
Raf-independent signaling in NIH 3T3 cells. To determine
whether the Raf/ERK effector pathway is involved in Ras-
mediated down-regulation of transgelin in RIE-1 cells, we as-
sessed whether treatment of RIE(Ras) cells with the U0126
MEK inhibitor to block ERK activation would cause any resto-
ration of transgelin expression. U0126-treated RIE(Ras) cells
showed the reappearance of transgelin expression (Fig. 4B).
Thus, although activation of the Raf/ERK pathway alone is not
sufficient to down-regulate transgelin expression in RIE-1
cells, it is necessary for full down-regulation by Ras.
Transgelin Is Deregulated in Human Tumor Cell Lines by
Ras-dependent and Ras-independent Mechanisms—Our analy-
ses showed that Ras transformation of rodent fibroblasts or
epithelial cells is associated with the loss of transgelin expres-
sion. We next determined whether transgelin expression is also
down-regulated by oncogenic Ras in human tumor cells. For
these analyses, we utilized two human tumor cell lines where it
has been shown that oncogenic Ras expression is critical for
promoting their transformed and tumorigenic growth proper-
ties (36, 37). Additionally, genetic variants of each have been
isolated that have lost the mutated ras allele. The DLD-1
human colon adenocarcinoma cell line contains a K-ras(13D)
mutant allele, and DKO3 is a variant cell line of DLD-1 where
the mutant ras allele was disrupted by homologous recombina-
tion. The HT1080 human fibrosarcoma cell line harbors a mu-
tant N-ras(61K) allele, and the MCH 603c8 cell line is a variant
of HT1080 that has lost the mutated N-ras allele. For both cell
lines, loss of mutant Ras function corresponded to impaired
ability for anchorage-independent growth in soft agar and tu-
mor formation in nude mice.
Northern blot analyses (Fig. 5) showed that transgelin ex-
pression was down-regulated in the ras mutation-positive pa-
rental HT1080 and DLD-1 cell lines and was elevated in the
MCH 603c8, but not DKO-3, ras mutation-deficient cell line.
These results show that loss of transgelin expression in the
HT1080 fibrosarcoma cell line, like that observed in the RIE-1
cell line, is Ras-dependent and in the DLD-1 colon adenocarci-
noma cell line is Ras-independent.
We further evaluated the role of Ras activation in down-
regulation of transgelin expression in additional human tumor
cell lines. First, we evaluated six colon carcinoma cell lines that
either harbor activating K-ras mutations (HCT116, SW480,
and HT29) or are wild type for ras (ColoHSR, Colo205, and
CaCo2). All of the human colon carcinoma cell lines also
FIG. 2. Northern blot analyses of genes up-regulated or down-
regulated by Ras but not Raf. Total RNA (25 g) from RIE-1 cells
stably transfected with empty vector (pZIP-NeoSV(x)1) or encoding
Raf-22W or K-Ras(12V) was isolated and size-fractionated by electro-
phoresis over formaldehyde-agarose gels and analyzed by Northern blot
with 32P-labeled DNA probes of each clone. A shows those genes up-
regulated by Ras, but not Raf, and the controls for RNA loading
(ethidium bromide staining and GAPDH) showing relative amounts of
RNA. B are those genes down-regulated by Ras but not Raf.
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showed a loss of expression of transgelin that was independent
of ras mutation status (Fig. 6). Similarly, whereas transgelin
expression was detected in the normal MCF-10A human breast
epithelial cell line, expression was lost in two human breast
carcinoma cell lines (MCF-7 and T47D) that also do not possess
mutated ras alleles. Thus, although aberrant activation of Ras
can cause down-regulating transgelin expression, Ras-inde-
pendent mechanisms must also exist in some tumor cells that
down-regulate its expression.
Transgelin Is Down-regulated in Human Breast and Colon
Tumors—Whereas our observations above and those of others
(31) have shown that transgelin expression is lost in trans-
formed and tumor cell lines, to date there have been no reports
showing aberrant expression of transgelin in patient-derived
human tumor tissue. Thus, to address this possibility, we per-
formed Northern blot analyses and compared the expression of
transgelin in patient-derived colon and breast tumor tissue
with matched adjacent nontumor histologically normal tissue
from the same patient. We found that transgelin expression
was greatly reduced or lost in all five colon and all four breast
tumor samples (Fig. 7). Furthermore, reduced transgelin ex-
pression was also seen in some nontumor colon (samples 4 and
5) and breast (samples 2 and 4). Because these samples may
represent benign tumor rather than normal tissue, it suggests
that loss of transgelin expression may be an early event in the
development of these cancers. These results demonstrate that
loss of transgelin expression is not restricted to cells in culture,
that transgelin expression is deregulated frequently in human
colon and breast tumors, and may represent an early event in
carcinogenesis.
Transgelin Is Down-regulated by Other Ras Family Small
GTPases—Transgelin is an actin-binding protein whose ex-
pression is decreased in association with the loss of stress fibers
(31). Rho family small GTPases, such as Rac1, RhoA, and
Cdc42, are regulators of actin cytoskeletal organization (42,
43). Furthermore, Rho family GTPases can be activated by
oncogenic Ras, and their functions are required by oncogenic
Ras to transform rodent fibroblasts (5). Therefore, we deter-
mined if activated RhoA, Rac1, or Cdc42 alone could also cause
down-regulation of transgelin gene expression. In addition, we
also determined if the down-regulation of transgelin by Ras
was Ras isoform-specific. For these analyses, we utilized RIE-1
cells stably transfected with expression vectors encoding con-
stitutively activated K-Ras(12V), Ha-Ras(61L), N-Ras(12D),
Rho(63L), and Rac1(61L) mutant proteins. In addition, cells
expressing constitutively activated Vav (an exchange factor
and activator of RhoA, Rac1, and Cdc42) and Dbl (an exchange
factor and activator of RhoA and Cdc42) were also utilized.3 As
shown in Fig. 8, relative to vector only transfected RIE-1 cells,
transgelin expression was down-regulated by K-, Ha-, and N-
Ras, partially down-regulated by Rac1 and Vav, but not by Raf,
RhoA, or Dbl. These results show that in addition to K-, Ha-,
and N-Ras, Rac and Vav are also capable of down-regulating
the expression of transgelin in RIE-1 cells. From these data, we
conclude that Vav is probably down-regulating transgelin
through Rac1 because Vav activates Rac, Rho, and Cdc42,
whereas Dbl, which activates Rho and Cdc42 (44), did not
down-regulate transgelin. Whereas these data might suggest
that Ras may mediate down-regulation of transgelin, in part
through activation of Rac1, we recently found that Rac-GTP
TABLE I
Genes up-regulated by Ras but not Raf
RDA
clone Sequence identity Species GenBank™ accession no. mRNA Identity
kb %
7 Potential ligand-binding protein (RY2G5) Rat X60660 2.5 99
8 Rat glia-derived nexin Rat M17784 2.6 100
34 Rat cartilage proteoglycan (aggrecan) Rat J03485.1 2.8 96
7.2
44 DNA-directed RNA polymerase II subunit RPB7 Rat Z71925 1.0 98
92 IMPDH Mouse M33934.1 3.0 93
46 Ribosomal subunit L27a Rat X52733 0.7 98






Genes down-regulated by Ras but not Raf
Clone Sequence identity Species GenBank™ accession no. mRNA Identity
kb %
22 Homolog of Drosophila pair-rule gene
odz/Tenm (ODZ3)
Mouse AF19518.1 7.9 91
23 Transgelin Rat X64422 1.0 99
24 Nidogen/Entactin (ENT) X14480 2.8 91
41 Tropomyosin Rat M60666 1.7 99
M60667
43 Protein tyrosine phosphatase  Mouse D13905 7.7 95
45 Stromal cell-derived factor-1  (/SDF-
1/TLSF)
Mouse L12030 2.9 89
3.6
47 Collagen -1(I) Rat Z78279.1 4.2 98
75 BMP-4 Z22607 1.6 97
17 Novel; homologous to human
pseudogene for chromogranin B
Human AL035461.1 3.8 83
1 5.5
30 Connexin-26 Rat X51015 3.5 99
39 Novel 6.5
48 Novel 5.9
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levels are actually down-regulated in Ras-transformed RIE-1
cells (data not shown). Thus, whereas Rac1 alone is capable of
mediating down-regulation of transgelin, Ras is probably not
down-regulating transgelin through Rac1. In addition, because
activated Rac1 alone does not cause transformation of RIE-1
cells (data not shown), loss of transgelin expression alone is not
sufficient to promote the morphologic transformation cause by
oncogenic Ras.
The Mechanism for Transgelin Transcriptional Repression
Does Not Involve Methylation of the Promoter—Transgelin ex-
pression is thought to be regulated at the level of transcription
(31, 45). Our results above showed that transgelin is down-
regulated at a high frequency in a variety of human tumor cell
lines and patient-derived tumor tissues suggesting that the
mechanism by which transgelin is down-regulated is one that
occurs frequently in carcinogenesis. One common mechanism
for suppression of gene expression in human carcinomas in-
volves DNA methylation of promoters of genes to block tran-
scription (46). For example, the expression of various tumor
suppressor genes, including BRCA1, E-cad, hMLH1, p16, VHL,
and Rb, are frequently inhibited due to hypermethylation in
human cancers. Additionally, promoter methylation has been
described as a mechanism to repress the transcriptional activ-
ity of transgelin in smooth muscle cells (47). Thus, we evalu-
ated the possibility that the loss of transgelin expression in
Ras-mediated transformation was due to DNA hyper-
methylation.
To determine whether transgelin expression was lost due
to DNA methylation, we treated RIE(Ras) cells with the
demethylating agent azadeoxyactidine and then examined,
by Northern blot analyses, the level of mRNA in treated cells
compared with vehicle only (Me2SO) treated cells. As shown
in Fig. 9, transgelin expression was not restored after 6 days
of treatment with azadeoxycytidine when compared with ve-
hicle only treated RIE(Ras) cells. In contrast, the expression
of tropomyosin, a gene we showed previously to be down-
FIG. 3. Down-regulation of transgelin correlates directly with
the temporal induction of Ha-Ras(61L) protein expression in
RIE-1 cells and not morphological transformation. Ha-Ras(61L)-
inducible RIE-1 cells were incubated in growth medium supplemented
with 1 mM IPTG for the times indicated and refed with growth medium
supplemented with fresh IPTG at 48 h, and duplicate cultures at each
time point were used for protein lysates or for isolation of total RNA.
Cells cultured without IPTG exhibited a flat, cobblestone appearance
typical of nontransformed RIE-1 cells and became highly morphologi-
cally transformed by the appearance of highly refractile, non-clustering,
spindly shaped cells after 96 h of IPTG treatment (A). Protein lysates
(30 g) were resolved by separation on 15% SDS-PAGE, transferred to
Immobilon-P, blotted with anti-Ha-Ras serum (146, Quality Biotechnol-
ogies) followed by horseradish peroxidase-conjugated secondary anti-
body, and visualized by ECL. Ha-Ras expression was detected by 6 h
after the addition of IPTG. Note that the Ha-Ras protein present at time
0 represents expression of endogenous Ras, and the reappearance of
unprocessed Ha-Ras at 72 h is due to the re-addition of IPTG (B). Total
RNA (25 g) was size-fractionated over formaldehyde-agarose gels,
transferred to Hybond-N (Amersham Biosciences), and hybridized to
32P-labeled cDNA probes of transgelin (C) or GAPDH (D), with the
latter used as a control for loading.
FIG. 4. Role of Raf in down-regulation of transgelin in RIE-1
and NIH 3T3 cells. A, activated Ras or Raf is sufficient to cause
down-regulation of transgelin in NIH 3T3 mouse fibroblasts. Total RNA
(25 g) was isolated from NIH 3T3 cells stably transfected with the
empty pZIP-NeoSV(x)1 vector or encoding Raf-22W or Ha-Ras(12V),
size-fractionated by electrophoresis over formaldehyde-agarose gels,
and analyzed by Northern blot with 32P-labeled transgelin cDNA probe.
B, inhibition of ERK activation partially restores transgelin expression
in RIE(Ras) cells. RIE(Ras) cells were treated for 24 or 48 h with Me2SO
(DMSO) vehicle control, with 10 M U0126, SB203580, or LY294002, or
with 50 M PD153035, and total RNA (25 g) was isolated, size-frac-
tionated by electrophoresis over formaldehyde-agarose gels, and ana-
lyzed by Northern blot with 32P-labeled DNA probes of transgelin or
GAPDH.
FIG. 5. Transgelin down-regulation in human epithelial cells is
mediated by Ras-dependent and Ras-independent mechanisms.
Total RNA (25 g) from DLD-1, DKS-3 (derivative of DLD-1 with
mutant K-ras(13D) allele deleted), HT1080 and MCH 603c8 (derivative
of HT1080 with mutant N-ras(61K) allele deleted) was size-fractionated
over formaldehyde-agarose gels and analyzed by Northern blot with
32P-labeled DNA probes for transgelin or GAPDH.
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regulated by Ras by DNA methylation, was restored after 6
days of treatment with azadeoxycytidine.3 These results sug-
gest that the mechanism by which transgelin expression is
down-regulated in Ras-transformed RIE-1 cells is not by
DNA methylation.
Forced Re-expression of Transgelin Alone Is Not Capable of
Reverting Ras-mediated Transformation of RIE-1 Cells—Our
determination that loss of transgelin expression is associated
with oncogenesis in a wide variety of cell types suggests that
transgelin may function to antagonize growth transformation.
Thus, we sought to determine whether forced re-expression of
transgelin could revert the transformed phenotype of RIE(Ras)
cells. We established mass populations of RIE(Ras) cells stably
transfected with an expression vector encoding HA epitope-
tagged transgelin, and we verified expression of HA-transgelin
by Western blot analyses using anti-HA serum (data not
shown). When compared with RIE(Ras) cells transfected with
the empty vector, those expressing HA-transgelin showed no
detectable change in either cell morphology or ability to grow in
soft agar (data not shown).
Because transgelin is an actin-binding protein, we also ex-
amined the possible role for the loss of transgelin in promoting
tumor cell invasion and metastasis. To address this question,
we utilized a human breast tumor cell line, MDA-MB-231, that
we showed does not express transgelin and that exhibits an
invasive phenotype in vitro (data not shown). Mass populations
of MDA-MB-231 cells stably overexpressing HA-tagged trans-
gelin were established similarly to those generated in the
RIE-1 cells, and expression of HA-transgelin protein was con-
firmed by Western blot analysis with anti-HA serum (data not
shown). By using two in vitro invasion assays, we next com-
pared the invasive phenotype of the parental MDA-MB-231
cells transfected with vector only (pBabe-HA) with that of the
cells expressing HA-transgelin using the Matrigel (48) and G8
myoblast (49, 50) invasion assays, and we found no difference
between the cells that did not and those that did express
transgelin (data not shown). Thus, these data show that forced
re-expression of transgelin alone is not sufficient to revert the
Ras-induced morphologic and growth transformation of RIE-1
cells or the invasive properties of MDA-MB-231 cells.
FIG. 6. Transgelin is frequently down-regulated in human tu-
mor cell lines. Total RNA (25 g) from normal breast epithelial cells
(MCF-10A), breast carcinoma cells (MCF-7 and T47D), colon carcinoma
cell lines without (ColoHSR, Colo205, and CaCo2) or with (HCT116,
SW480, and HT29) activating K-ras mutations and from RIE-1 cells as
a positive control for detection of transgelin mRNA was size-fraction-
ated by electrophoresis over formaldehyde-agarose gels and analyzed
by Northern blot with 32P-labeled DNA probes of transgelin or GAPDH.
FIG. 7. Transgelin expression is frequently down-regulated in
patient-derived colon and breast tumor tissue. Total RNA (25 g)
from nontumor (N) and tumor (T) tissues of the colon (A) or breast (B)
were size-fractionated by electrophoresis over formaldehyde-agarose
gels and analyzed by Northern blot with 32P-labeled DNA probes of
transgelin or GAPDH as a control for loading.
FIG. 8. Transgelin is down-regulated by Rac1 and Vav in RIE-1
cells. Total RNA (25 g) from RIE-1 cells stably expressing empty
vector (pZIP-NeoSV(x)1) or expressing constitutively activated Raf-
22W, K-Ras(12V), Ha-Ras(12V), N-Ras(12D), Rho(63L), Rac(61L),
Vav(N186), and Dbl-HA1 was size-fractionated over formaldehyde-
agarose gels and analyzed by Northern blot with 32P-labeled DNA
probes of transgelin or GAPDH as a control for loading.
FIG. 9. The mechanism by which transgelin is down-regulated
by Ras is not mediated by DNA methylation. RIE-1 cells stably
expressing K-Ras(12V) were treated with the demethylation agent
5-aza-2deoxycytidine (Sigma) at 1 M for 3 or 6 days or with vehicle
(Me2SO) alone for 6 days, and total RNA was isolated, size-fractionated
by electrophoresis over formaldehyde-agarose gels, and analyzed by
Northern blot with 32P-labeled DNA probes of transgelin or GAPDH as
a control for loading. Untreated RIE-1 cells expressing the empty vector
(pZIP-NeoSV(x)1) were used as a positive control for detection of trans-
gelin transcript.
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DISCUSSION
We have shown that whereas activated Ras and Raf can fully
transform NIH 3T3 fibroblast cells, only activated Ras can
cause transformation of RIE-1 and other epithelial cells (24).
Consequently, Ras activation of Raf-independent effector sig-
naling pathways is critical for transformation of these and
other epithelial cells. To elucidate further the nature of Raf-
independent signaling important for Ras transforming activity,
we used RDA and identified those genes whose expression was
deregulated by Ras transformation through Raf-independent
pathways in RIE-1 intestinal epithelial cells. We identified 10
genes whose expression was up-regulated and 12 genes that
were down-regulated by Ras-, but not Raf-, expressing RIE-1
cells. Both known (15) and novel (6) genes, as well as one EST
sequence, were identified. These observations support the im-
portant role of Raf-independent effectors in causing changes in
gene expression and the importance of gain as well as loss of
gene expression in Ras-mediated transformation. Finally, we
identified transgelin as a gene down-regulated by Ras in RIE-1
cells, and we determined that a reduction in transgelin gene
expression is a common event associated with human breast
and colon carcinogenesis. However, forced re-expression of
transgelin did not reverse Ras transformation of RIE-1 or NIH
3T3 (data not shown) cells or impair the invasive properties of
breast carcinoma cell lines in vitro. In light of the multitude of
gene expression changes seen in Ras-transformed cells, it is not
surprising that the correction of one gene expression defect
alone will not be sufficient to reverse Ras transformation.
In an analysis of the genes we isolated by RDA, we found
that all genes identified were up- or down-regulated by Ras, but
not Raf, in RIE-1 cells. The only exception was connexin-26,
which was down-regulated by Ras but up-regulated by Raf.
This suggests that perhaps Raf-dependent signaling positively
regulates connexin-26 expression, whereas Raf-independent
pathways negatively regulate connexin-26 expression. Thus,
the Raf-independent pathways activated by Ras that inhibit
connexin-26 transcription may override a positive signal trans-
duced from the Raf/MEK/ERK pathway and result in transcrip-
tional repression of connexin-26.
Our observation of significant changes in gene expression in
RIE(Ras) versus RIE(Raf) cells indicates that an important
consequence of Raf-independent signaling is the changes in
gene expression. The observations that we obtained using RDA
are similar to those made by Schäfer and colleagues (51), where
they utilized subtractive suppression hybridization, a similar
PCR-based cDNA subtraction technique, and identified 393
known or novel genes whose expression was up-regulated or
down-regulated by Ras transformation of 208F rat fibroblasts.
Of these genes, the expression of only 61 genes was reversed by
treatment of Ras-transformed cells with pharmacological inhi-
bition of ERK activation, indicating that the majority of gene
expression changes caused by Ras are mediated by activation of
Raf-independent signaling pathways.
In another study using microarray analyses of over 6,000
human genes, Downward and colleagues (25) identified 124
genes that were differentially expressed upon Raf activation in
MCF-10A human breast epithelial cells. As with RIE-1 cells,
Raf activation alone is not sufficient to cause transformation of
MCF-10A cells (24, 25). Interestingly, the vast majority (85%)
of these genes were up-regulated rather than down-regulated
in expression. This contrasts with our observation where we
found an equivalent number of genes up-regulated and down-
regulated by oncogenic Ras. Thus, it appears that Raf activa-
tion involves primarily activation of gene expression, whereas a
significant consequence of Raf-independent effector activation
involves down-regulation of gene expression.
Interestingly, a number of the genes up-regulated by Ras in
RIE-1 cells have been shown previously to be associated with
oncogenesis. For example, we identified IMP dehydrogenase II
(IMPDH II) as a gene up-regulated by Ras. IMPDH II is the
rate-limiting enzyme in GTP biosynthesis, and its activity has
been found to be up-regulated in many cancer cells, although
no association with Ras activation has been described previ-
ously (52). Inhibitors of IMPDH II have been evaluated for use
in cancer chemotherapy, and we are currently assessing the
consequence of IMPDH II inhibition on the transformed growth
properties of RIE(Ras) cells. Similarly, we found that glial-
derived nexin I was up-regulated by Ras, and glial-derived
nexin I activity was shown to be increased in 9L rat brain
gliosarcoma cells (53).
We also found that genes down-regulated by Ras have been
described previously as genes whose products may be antago-
nistic to epithelial cell growth. For example, we found that the
gene expression of thymic lymphoma cell stimulating factor-
(TLSF-)/stromal cell-derived factor- (SDF-1) was down-reg-
ulated by Ras. SDF-1 is a cytokine for the chemokine receptor
CXCR-4 that is thought to be responsible for B-cell lymphopoi-
esis and bone marrow myelopoiesis (54). Although TLSF-/
SDF-1 stimulates the growth of lymphocytes, it may inhibit
the growth of epithelial cells and, consequently, function sim-
ilarly to transforming growth factor- in its opposing conse-
quences on the growth of mesenchymal versus epithelial cells
(55). In addition, expression of the closely related gene SDF-1
was greatly reduced in a majority of gastrointestinal tumors
(56). When taken together, these observations suggest that the
loss of expression of TLSF-/SDF-1 may contribute to Ras-
mediated transformation.
The protein products of several genes down-regulated by Ras
have been implicated in the regulation of cell-cell and/or cell-
matrix interactions. Nidogen/entactin is a component of base-
ment membranes and has been shown to promote cell attach-
ment (57) and differentiation (58) of mouse mammary tumor
cells. Another down-regulated gene encodes connexin-26, a gap
junctional intercellular communication protein. Decreased ex-
pression of connexins is associated with the down-regulated
loss of gap junctional intercellular communication protein,
which has been associated with uncontrolled cell growth and
neoplasia (59) and is thought to be an early event in tumor
progression (60). In addition, although normal mammary epi-
thelial cells express predominantly connexin-26, little to none
is detected in breast cancers (61). We have found that gap
junctions are disrupted in RIE(Ras) cells, and this loss may
represent an important event in Ras transformation.4 Finally,
our identification of tropomyosin as a gene down-regulated in
RIE(Ras) cells is consistent with previous studies (62–64)
where loss of its RNA and protein expression has been associ-
ated with Ras transformation of a variety of fibroblast and
epithelial cells. Decreased expression of tropomyosin has also
been observed in human prostate, breast, and ovarian tumors
and in squamous cell carcinoma tissues (65–67). Tropomyosin
is an actin-binding protein of unknown function, and its forced
re-expression in Ras-transformed fibroblasts has been shown
to reverse morphologic and growth transformation. However,
our recent studies3 determined that forced re-expression of
tropomyosin in Ras-transformed RIE-1 cells did not cause any
significant reversal of transformation.
Finally, we found that transcripts for bone morphogenetic
protein (BMP)-4 were down-regulated by Ras in the RIE-1
cells. BMP-4 is a member of the transforming growth factor-
4 J. M. Shields, K. Rogers-Graham, and C. J. Der, unpublished
observations.
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family (68), and BMP-4 has been shown to induce the cyclin-
dependent kinase inhibitor p21 (69) and apoptosis (68, 70, 71).
Thus, the loss of expression of BMP-4 may promote the growth
and survival of Ras-transformed RIE-1 cells. This observation,
when taken together with the fact that a number of the genes
that we have identified have been linked previously to onco-
genesis, supports the possibility that these gene expression
changes may indeed be important in mediating Ras transfor-
mation via activation of Raf-independent signaling pathways.
Thus, the long term goal of our studies will be to determine
whether genes down-regulated by Ras but not Raf, when re-
expressed in RIE(Ras) cells, cause a reversion of Ras transfor-
mation. Conversely, we will determine whether genes up-reg-
ulated by Ras but not Raf cause growth transformation when
forced-overexpressed in RIE(Raf) cells.
In the present study, we extended our analyses to evaluate
the regulation of transgelin expression by Ras and its role in
Ras-mediated transformation. Transgelin was identified previ-
ously as a transformation and shape change-sensitive actin-
gelling protein (40). However, only limited analyses have been
done to evaluate the mechanism of down-regulation. Further-
more, no evaluation of transgelin expression in human cancers
had been done. First, we showed that the expression of trans-
gelin is abolished at the level of transcription by oncogenic Ras
in NIH 3T3 mouse fibroblasts, RIE-1 rat intestinal epithelial
cells, and HT1080 human fibrosarcoma cells. Second, we
showed that transgelin expression was down-regulated in a
variety of human breast, colon, and fibrosarcoma tumor cell
lines. However, the absence of transgelin expression in breast
and colon carcinoma cell lines that lack ras mutations indicates
that Ras-independent mechanisms of down-regulation also ex-
ist. In addition, it remains possible that in those cell lines that
harbor a mutant ras allele, the mechanism by which transgelin
is down-regulated may also be independent of Ras activity.
However, because our analyses of RIE-1 and HT1080 cells
showed that transgelin down-regulation is dependent on Ras
expression in these cell types, we would expect that down-
regulation of transgelin in some tumor cell lines can be through
a Ras-dependent mechanism. Finally, we showed that transge-
lin expression was lost in a large number of human colon and
breast tumor samples. Thus, this is the first report showing
transgelin to be down-regulated in vivo.
We observed that down-regulation of transgelin was associ-
ated with the temporal expression of oncogenic Ras, rather
than with the onset of the transformed phenotype. This sup-
ports a possible contribution of the loss of transgelin expression
in mediating Ras transformation. However, when we forced
re-expressed transgelin in Ras-transformed RIE-1 cells, we saw
no change in morphology or ability to grow in soft agar. In
addition, we also found that coexpression of transgelin was not
capable of inhibiting Ras-mediated transformation of NIH 3T3
cells (data not shown). We also found that re-expression of
transgelin did not reduce the invasive properties of the MDA-
MD-231 breast tumor cells. These results do not necessarily
mean that the loss of transgelin is not involved in Ras-medi-
ated transformation because it is likely that the correction of
one gene defect alone will not be sufficient to reverse Ras
transformation. For example, we also found that the expression
of another actin-binding protein, tropomyosin, is lost in Ras-
transformed cells. Perhaps the re-expression of transgelin, to-
gether with tropomyosin, will be required to reverse the mor-
phologic transformation seen with Ras-transformed cells.
Finally, it is also possible that the addition of an NH2-terminal
HA epitope tag onto transgelin impaired its function or that
ectopic overexpressed transgelin will not be incorporated prop-
erly into actin. In the absence of clear functional assays for
transgelin function, these possibilities cannot be excluded.
In summary, we have identified a collection of genes aber-
rantly expressed as a result of Ras transformation through
Raf-independent pathways in RIE-1 colonic epithelial cells.
Our observations, when considered together with those made
by Schäfer and colleagues (51), indicate that changes in gene
expression are clearly associated with Ras activation of Raf-
independent effectors. With the increasing application of gene
array expression analyses, the roster of Ras-deregulated genes
is certain to expand significantly. Thus, the task at hand will be
to identify those changes in gene expression that are important
mediators of oncogenic Ras transformation. Such genes may
identify novel targets for anti-Ras drug development as well as
markers for the early detection of ras mutation-positive
cancers.
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